Home
Daily News from Ghana Ghana Sports Information about Ghana Opinions Classifieds Web Directory
Latest News
Headlines
Election 2008
Entertainment
Business
Crime & Punishment
Ghanaians Abroad
Health
Politics
Regional
Religion
Sports
Tabloid
Advertisement




Others
Poll
Search News
Rumour Mill
Events Schedule
Press Release
World News
Ghanaian Media
Accra Daily Mail
Chronicle
Crusading Guide
Daily Graphic
District News
Ghanaian Times
Ghana Review
Daily Guide
Government News
Joy Online
Peace FM
Public Agenda
The Palavar
The Statesman
MORE....
Other Media
allAfrica
BBC-Africa News
Africanews.com
Search Site Map Printer Version Contact us
Previous Article Health News of Friday, 3 July 2009 Next Article

WHO introduces new drug for river blindness

Accra, July 3, GNA - A clinical trial to introduce a new drug to eliminate river blindness has been launch by the World Health Organization (WHO) in three African countries.

The drug is called Moxidectine, which is being investigated for its potential to kill or sterilize adult worms of Onchocerca Volvulus, which causes river blindness.

The drug has a potential to interrupt the disease transmission cycle within around six annual rounds of treatment.

The drug is a veterinary marcocyclic lactone drug.

A press release signed by Jamie Guth, Communication Manager for Training in Tropical Diseases, received by GNA on Friday, stated the trial, which started in April 2007, would run for two-and-a-half years in Ghana, Liberia and Democratic Republic of Congo.

Each country would be provided with the necessary equipment and research teams trained on how to conduct the trial according to international standards and in Ghana, the trial would be conducted in the Volta Region. The objective of the Africa Programme for Onchocereciasis Control was to establish within a period of 12 to 15 years an effective, self-sustainable and community directed treatment with Ivermectine throughout the endemic areas within the geographic scope of the programme, develop the evidence base and assist countries to determine when and where Ivermectine treatment can be stopped.

"The Moxidectine data have been promising so far, and as the programme moves into a larger phase three studies, we are hopeful that moxidectine will constitute a significant advance against the devastating disease," the release said.

The studies were aimed at providing data on Moxidectine in subjects infected with Onchocerca Volvulus for determination of safety, tolerability and efficacy.

The exact mechanism of action of Moxidectine is still under investigation.

The statement said the disease had been controlled by Invermectine, which was donated by the Pharmaceutical Merck Company to river blindness endemic countries.

River Blindness is an eye and skin disease caused by the parasitic worm Onchocerca Volvulus, which is transmitted from person-to-person through the bite of black flies of the genus simulium. The disease is the world's second leading infection cause of blindness. 3 July 09

Source:
GNA
Read more articles Discuss this article on Say It Loud Email this article to a friend Print this article

Comments:


All Rights Reserved, 1994-2009, © Copyright GhanaHomePage